BioArctic reported strong Q1 2026 results driven by Leqembi, an Alzheimer's drug co-developed with Eisai. Sales surpassed €500 million in Eisai's fiscal year 2025, triggering a €20 million milestone payment. The FDA granted Priority Review for Leqembi's subcutaneous formulation but extended the review period to August 24, 2026. New long-term data show sustained disease-slowing effects up to four years. Despite regulatory progress globally, Sweden's NT Council currently does not recommend Leqembi's introduction. Eisai forecasts 63% sales growth for fiscal 2026, signaling continued momentum for the treatment and BioArctic's research pipeline.
On May 20, 2026, Equinor ASA allocated shares to certain primary insiders and their close associates as part of its employee share savings and long-term incentive programs. The shares were granted at a price of NOK 356.31 each under the long-term inc...
SalMar ASA reported a significant profit improvement in Q1 2026 driven by higher harvest volumes, better fish quality, and lower costs. Operational EBIT for Norway reached NOK 1,536 million with a harvest volume of 56,300 tons, while the group’s tota...
SalMar ASA reported a significant improvement in Q1 2026 results, driven by higher harvest volumes, better fish quality, and lower costs. Operational EBIT for Norway reached NOK 1,536 million with a harvest volume of 56,300 tonnes. The company experi...
XRP has declined 12% over five trading days, breaking below the critical $1.40 support level and forming a bearish pennant pattern that projects a possible drop to $0.65. Technical indicators like the weekly Stochastic RSI signal further downside ris...
Solana's native token SOL fell about 15% after failing to surpass the $98 resistance level, now trading near $85. Bearish market sentiment is indicated by negative perpetual futures funding rates at -3%. Weekly decentralized exchange (DEX) transactio...
